ASH 2023 | Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, explores the targeting of mitochondrial metabolism to eliminate measurable residual disease (MRD) following induction chemotherapy in acute myeloid leukemia (AML). Mitochondrial inhibitor IACS-010759 has shown promise in reducing tumor burden in animal models, but this agent has shown toxicity in clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Current holder of stock options: Reata Pharmaceuticals
Patents & Royalties: Reata Pharmaceuticals
Consultancy: AbbVie, AstraZeneca, Genentech, Gilead, Janssen, MEI Pharma, Sanofi Aventis, Stemline-Menarini, Vincerx
Research Funding: AbbVie, Ablynx, Allogene, AstraZeneca, Cellectis, Daiichi, FortySeven, Genentech, Gilead, Immunogen, MEI Pharma, Precision Biosciences, Rafael Pharmaceutical, Sanofi Aventis, Stemline-Menarini
